Toward a single dose cure for Buruli ulcer
Abstract
A single dose of TELACEBEC (Q203), a phase 2 clinical candidate for tuberculosis, eradicates Mycobacterium ulcerans in a mouse model of Buruli ulcer infection without relapse up to 19 weeks post treatment. Clinical use of Q203 could dramatically simplify the clinical management of Buruli ulcer, a neglected mycobacterial disease.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Impact of dose, duration and host immune status on ultrashort telacebec treatment in a mouse model of Buruli ulcer
P. J. Converse, D. Almeida, … E. Nuermberger·bioRxiv·Jun 22, 2021
- Telacebec for ultra-short treatment of Buruli ulcer in a mouse model
D. Almeida, P. J. Converse, … E. Nuermberger·bioRxiv·Feb 10, 2020
- Ultrashort treatment with telacebec alone and with companion drugs in immunocompetent and immunosuppressed mouse footpad models of Buruli ulcer
P. J. Converse, O. Komm, … E. Nuermberger·bioRxiv·Jun 22, 2021
- Q203 containing fully intermittent oral regimens exhibited high sterilizing activity against Mycobacterium ulcerans in mice
A. Chauffour, J. Robert, … V. Jarlier·bioRxiv·Oct 21, 2019
- A composite subunit vaccine confers full protection against Buruli ulcer disease in the mouse footpad model of Mycobacterium ulcerans infection
Justice Kofi Boakye-Appiah, Andy Cano Tran, … Rajko Reljić·PLoS neglected tropical diseasesPeer-reviewed·Feb 21, 2025
- Triple oral beta-lactam containing therapy for Buruli ulcer treatment shortening
M. P. Arenaz Callao, R. Gonzalez del Rio, … S. Ramon-Garcia·bioRxiv·Oct 11, 2018